V souladu s legislativou České republiky poskytuje Společnost služby pouze kvalifikovaným investorům!

Achilles Therapeutics. Financial results for the second quarter of 2021.

10.08.2021

GAAP net loss is -$0.45, that is $0.08 better than the same period last year.
Cash and cash equivalents are $299.3 million as of June 30, 2021.